Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan open-label extension study of beremagene geperpavec for dystrophic epidermolysis bullosa
jRCT2053230075Completed
- Sponsor
- Krystal Biotech, Inc.
- Start
- Sep 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 2
01
Overview
Open-label, single-arm trial of beremagene geperpavec in dystrophic epidermolysis bullosa (DEB), sponsored by Krystal Biotech, Inc. Primary endpoint: Wound healing at 6 months. Started Sep 2023; status: completed.
02
Drugs
beremagene geperpavec
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on jRCT2053230075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053230075.